Time to Go Overweight on Obesity-Drug Makers?
The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and consumer-goods editor and analyst Austin Smith discuss topics around the investing world.
In this video, David and Austin discuss the recent news surrounding obesity-drug makers. With an overwhelmingly favorable FDA advisory panel recommending approval for Qnexa by a 20-2 vote, what does that mean for its maker, VIVUS, and for its competitors Arena Pharmaceuticals and Orexigen? Is Qnexa poised to reap all of the rewards?
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time this article was published Austin Smith has no positions in the stocks mentioned above. David Williamson and The Motley Fool own shares of Johnson & Johnson.Motley Fool newsletter services recommendJohnson & Johnson. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.